🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Aspen Aerogels stock price target cut, overweight held on developments

EditorNatashya Angelica
Published 22/10/2024, 14:26
ASPN
-

On Tuesday, Piper Sandler adjusted its stock price target for Aspen Aerogels (NYSE:NYSE:ASPN), a company specializing in energy-efficient aerogel insulation, to $33.00, down from the previous $36.00 target. The firm maintained its Overweight rating on the stock.

The revision follows two significant developments related to the company. Aspen Aerogels announced a secondary offering after the market closed, which came shortly after reporting strong third-quarter results and securing a loan from the Department of Energy (DOE). The offering is expected to result in dilution of the shares.

Moreover, Piper Sandler took into account the final production and sales figures for September from General Motors (NYSE:GM), Aspen's largest customer in the electric vehicle sector. These figures were integral to the firm's reassessment of Aspen Aerogels' financial outlook.

Despite the reduction in the price target, Piper Sandler remains positive about Aspen Aerogels' prospects. The firm believes that with the company's balance sheet concerns now fully addressed, attention can shift to the anticipation of new customer awards. Furthermore, there are upcoming construction milestones at Aspen's new manufacturing facility in Georgia, which are seen as positive indicators for the company's future growth.

Piper Sandler's report suggests confidence that these recent developments, while impacting the short-term valuation, do not detract from the long-term potential of Aspen Aerogels in the market. The firm's ongoing recommendation to invest in ASPN shares reflects this outlook.

In other recent news, Aspen Aerogels announced the launch of a public stock offering of 4,250,000 shares. The proceeds are intended for working capital, capital expenditures, and general corporate purposes. Goldman Sachs (NYSE:GS) & Co. LLC and Morgan Stanley (NYSE:MS) are managing the offering.

Aspen Aerogels also reported third-quarter revenues of approximately $117 million and an adjusted EBITDA of $25 million, surpassing expectations. This performance is primarily attributed to robust sales of the company's EV Thermal Barriers product line.

The company has also received a conditional approval for a Department of Energy (DOE) loan to fund the completion of its second manufacturing plant, known as Plant II. This loan is expected to support the production of Aspen Aerogels’ PyroThin aerogel blankets, which could generate annual revenues between $1.2 billion and $1.6 billion.

Several analyst firms, including H.C. Wainwright, Seaport Global Securities, Roth/MKM, TD Cowen, and Oppenheimer, have maintained their positive ratings on Aspen Aerogels.

InvestingPro Insights

Aspen Aerogels' recent developments align with several key metrics and insights from InvestingPro. The company's revenue growth is particularly noteworthy, with a 144.55% increase in quarterly revenue as of Q2 2024. This robust growth supports Piper Sandler's optimistic outlook despite the reduced price target.

InvestingPro Tips highlight that Aspen Aerogels' net income is expected to grow this year, and analysts anticipate sales growth in the current year. These projections align with the company's recent strong third-quarter results mentioned in the article. Moreover, the tip indicating that liquid assets exceed short-term obligations suggests that the company's balance sheet concerns, as addressed in the article, may indeed be improving.

It is worth noting that ASPN's stock has shown a strong return over the last year, with a 209.13% price total return. This performance, coupled with the company's growth prospects, may explain why Piper Sandler maintains its Overweight rating despite the price target adjustment.

For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Aspen Aerogels, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.